Table 1 Patient characteristics by group
Characteristic | Ineligible (n = 34) | Eligible (n = 169) | Total (n = 203) | P-value* | |
|---|---|---|---|---|---|
Median age | Median [range] | 54.0 [31–77] | 58.0 [30–81] | 58.0 [30–81] | 0.179 |
Performance status (%) | 0 | 18 (52.9) | 88 (52.1) | 106 (52.2) | 0.231 |
1 | 13 (38.2) | 74 (43.8) | 87 (42.9) | ||
2 | 2 (5.9) | 7 (4.1) | 9 (4.4) | ||
3 | 1 (2.9) | 0 (0.0) | 1 (0.5) | ||
Hormone receptor positive (%) | 20 (58.8) | 134 (79.3) | 154 (75.9) | 0.024 | |
Her2+ (%)a | 4 (11.8) | 23 (13.6) | 27 (13.3) | 1.000 | |
Metastatic sites ≥3 (%) | 13 (38.2) | 56 (33.1) | 69 (34.0) | 0.559 | |
Liver metastasis (%) | 24 (70.6) | 93 (55.0) | 117 (57.6) | 0.128 | |
Lung metastasis (%) | 17 (50.0) | 69 (40.8) | 86 (42.4) | 0.346 | |
Bone only (%) | 1 (2.9) | 2 (1.2) | 3 (1.5) | 0.425 | |
Target lesion present (%) | 32 (94.1) | 144 (85.2) | 26 (12.8) | 0.387 | |
Prior surgery (%) | 30 (88.2) | 139 (82.2) | 169 (83.3) | 0.462 | |
No. of prior chemotherapy lines | Median [range] | 3 [2–8] | 3 [1–11]b | 3 [1–11] | 0.294 |
No. of prior chemotherapy lines for advanced disease | Median [range] | 2 [0–7] | 2 [0–9] | 2 [0–9] | 0.204 |